Skip to main
DBVT

DBVT Stock Forecast & Price Target

DBVT Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

DBV Technologies is a late clinical-stage biopharmaceutical company that is developing a novel technology platform called Viaskin, which is a skin patch that delivers biologically active compounds to the immune system. The company's lead product candidate, Viaskin Peanut, is in development for the treatment of peanut-allergic patients and has shown positive results in clinical trials. The company also has other food allergy programs in earlier stages of development. With their innovative EPIT approach and positive clinical data, DBV Technologies has the potential to change the immunotherapy landscape and become a leader in the treatment of food allergies. However, potential risks include delays in BLA submissions and setbacks in clinical, regulatory, or commercial plans. Overall, given the company's strong financial position and potential for market leadership in the food allergy space, a positive outlook is warranted.

Bears say

DBV Technologies is facing potential headwinds due to its focus on a single product candidate, Viaskin Peanut, and its reliance on the success of this product for its future growth. While the company's anticipated YE26 net cash position and continued execution on commercialization efforts are strengths, high expectations for peak US sales of ~$3B may not be realistic, and competition from established players in the allergy space may hinder market share. As a result, our $51 price target, based on a sum-of-the-parts analysis, reflects a cautious outlook on DBV's stock performance.

DBVT has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DBV Technologies SA Sponsored ADR (DBVT) Forecast

Analysts have given DBVT a Buy based on their latest research and market trends.

According to 4 analysts, DBVT has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DBV Technologies SA Sponsored ADR (DBVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.